The Ryplazim numbers alone still are staggering to considerThe math is staggering. If Prometic is charging an estimated $75,000 per/year for Ryplazim, and at 100% U.S. market penetration only , the estimated gross sales are as follows:
Plasminogen Deficiency = $150 million (2,000 U.S. patients)
IPF = ? (Ryplazim use only) (25,000 acute U.S. patients)
Acute Lung Injury = $15 Billion (200,000 U.S. patients)
Severe Burns = $1.125 Billion (15,000 U.S. patients)
Aquired Acute Deficiency = $7.5 Billion (100,000 U.S. patients)
Ophthalmic Indications = $7.5 Billion (100,000 U.S. patients)
Tympanic Repair = $6 Billion (80,000 U.S. patients)
Diabetic Foot Ulcers = $37.5 Billion (500,000 U.S. patients)
*Of course you’ll never get 100% U.S. market penetration, but then you have the ROW (rest of world) patient population to consider, and also consider there is no competition for the next few years; Prometic will be first to market and own the plasminogen market.
These numbers are staggering for Ryplazim use only; then add pbi-4050 in the mix and you can see why I’m laughing at these negative posters like GunnerG who only post negativity on this board.
The year 2020 remains my horizon for the fireworks to begin(4050 in the U.K. & Ryplazim on the market), so I still don’t care about today’s pps, or yesterday’s pps, or tomorrow’s pps.... etc.
PLI remains a good buying opportunity under $1 USD imo.